Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers

• Autor: Pereira, Elena ; Camacho-Vanegas, Olga ; Anand, Sanya ; Sebra, Robert ; Catalina Camacho, Sandra ; Garnar-Wortzel, Leopold ; Nair, Navya ; Moshier, Erin ; Wooten, Melissa ; Uzilov, Andrew ; Chen, Rong ; Prasad-Hayes, Monica ; Zakashansky, Konstantin ; Beddoe, Ann Marie ; Schadt, Eric ; Dottino, Peter ; Martignetti, John A
• Samimi, Goli
• Assuntos: Adult ; Aged ; Biological markers ; Biomarkers ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - mortality ; CA-125 Antigen - blood ; Cancer ; Cancer therapies ; Chemotherapy ; Computed tomography ; Deoxyribonucleic acid ; Diagnostic systems ; DNA ; DNA probes ; DNA, Neoplasm - blood ; DNA, Neoplasm - genetics ; Endometrial cancer ; Endometrial Neoplasms - blood ; Endometrial Neoplasms - drug therapy ; Endometrial Neoplasms - genetics ; Endometrial Neoplasms - mortality ; Endometrium ; Exome - genetics ; Fallopian tube ; Female ; Female genital cancer ; Gene sequencing ; Genital cancer ; Genital Neoplasms, Female - blood ; Genital Neoplasms, Female - drug therapy ; Genital Neoplasms, Female - genetics ; Genital Neoplasms, Female - mortality ; Gynecology ; Humans ; Imaging ; Lead time ; Medicine ; Middle Aged ; Mutation ; Mutation - genetics ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - genetics ; Obstetrics ; Ovarian cancer ; Ovarian carcinoma ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - mortality ; Patients ; Peritoneum ; Physiological aspects ; Plasma ; Precision medicine ; Prognosis ; Quality ; Reproductive system ; Scanning ; Surgery ; Surveillance ; Survival ; Tumors ; Uterine cancer ; Womens health
• É parte de: PloS one, 2015-12, Vol.10 (12), p.e0145754-e0145754
• Notas: ObjectType-Article-1
  SourceType-Scholarly Journals-1
  ObjectType-Feature-2
  content type line 23
  Competing Interests: The authors have declared that no competing interests exist.
  Conceived and designed the experiments: EP OCV RS PD JAM. Performed the experiments: EP OCV SA SCC LGW MW RS. Analyzed the data: EP OCV SA RS AU SCC NN EM PD JAM. Contributed reagents/materials/analysis tools: MPH KZ AMB RC ES PD. Wrote the paper: EP OCV PD JAM.
  
• Descrição: High-grade serous ovarian and endometrial cancers are the most lethal female reproductive tract malignancies worldwide. In part, failure to treat these two aggressive cancers successfully centers on the fact that while the majority of patients are diagnosed based on current surveillance strategies as having a complete clinical response to their primary therapy, nearly half will develop disease recurrence within 18 months and the majority will die from disease recurrence within 5 years. Moreover, no currently used biomarkers or imaging studies can predict outcome following initial treatment. Circulating tumor DNA (ctDNA) represents a theoretically powerful biomarker for detecting otherwise occult disease. We therefore explored the use of personalized ctDNA markers as both a surveillance and prognostic biomarker in gynecologic cancers and compared this to current FDA-approved surveillance tools. Tumor and serum samples were collected at time of surgery and then throughout treatment course for 44 patients with gynecologic cancers, representing 22 ovarian cancer cases, 17 uterine cancer cases, one peritoneal, three fallopian tube, and one patient with synchronous fallopian tube and uterine cancer. Patient/tumor-specific mutations were identified using whole-exome and targeted gene sequencing and ctDNA levels quantified using droplet digital PCR. CtDNA was detected in 93.8% of patients for whom probes were designed and levels were highly correlated with CA-125 serum and computed tomography (CT) scanning results. In six patients, ctDNA detected the presence of cancer even when CT scanning was negative and, on average, had a predictive lead time of seven months over CT imaging. Most notably, undetectable levels of ctDNA at six months following initial treatment was associated with markedly improved progression free and overall survival. Detection of residual disease in gynecologic, and indeed all cancers, represents a diagnostic dilemma and a potential critical inflection point in precision medicine. This study suggests that the use of personalized ctDNA biomarkers in gynecologic cancers can identify the presence of residual tumor while also more dynamically predicting response to treatment relative to currently used serum and imaging studies. Of particular interest, ctDNA was an independent predictor of survival in patients with ovarian and endometrial cancers. Earlier recognition of disease persistence and/or recurrence and the ability to stratify into better and worse outcome groups through ctDNA surveillance may open the window for improved survival and quality and life in these cancers.
  
• Editor: United States: Public Library of Science
  
• Idioma: Inglês